Form 4: Nuvation Bio Inc. Chief Medical Officer Acquires Shares and Stock Options

Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., reports acquisition of shares and stock options in the company.

Summary

• Dongfang Liu, the Chief Medical Officer of Nuvation Bio Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates that Liu acquired 6,000 shares of Class A Common Stock.
• These shares include 3,000 shares acquired on May 19, 2023, and 3,000 shares acquired on November 17, 2023, under the Issuer's 2021 Employee Stock Purchase Plan.
• Liu also acquired stock options for 500,000 shares of Class A Common Stock at an exercise price of $1.87.
• The options vest as to 25% on the one-year anniversary of February 29, 2024, and then monthly over the following 36 months, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating stock and option acquisitions by an executive, which can be seen as a positive sign of confidence, but it's not overwhelmingly positive.

Positives

• The acquisition of shares and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the executive's stock and option acquisitions as a positive signal.

Key Dates